Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database

• Main Authors: Charan, Jaykaran, Dutta, Siddhartha, Kaur, Rimplejeet, Bhardwaj, Pankaj, Sharma, Parveen, Ambwani, Sneha, Jahan, Iffat, Abubakar, Abdullahi Rabiu, Islam, Salequl, Hardcastle, Timothy Craig, A. Rahman, Nor Azlina, Lugova, Halyna, Haque, Mainul
• Format: Article
• Language: English; English
• Published: Taylor & Francis 2021
• Subjects: RS403 Materia Medica-Pharmaceutical Chemistry
• Online Access: http://irep.iium.edu.my/93893/7/93893_Tocilizumab%20in%20COVID-19%20a%20study%20of%20adverse%20drug_SCOPUS.pdf; http://irep.iium.edu.my/93893/8/93893_Tocilizumab%20in%20COVID-19%20a%20study%20of%20adverse%20drug.pdf; http://irep.iium.edu.my/93893/; https://www.tandfonline.com/toc/ieds20/current; https://doi.org/10.1080/14740338.2021.1946513

leading to pneumonitis with a poor prognosis. Tocilizumab, a type of humanized monoclonal antibody antagonizing interleukin-6 receptors, is currently utilized to treat COVID-19. The present study reviews tocilizumab adverse drug events (ADEs) reported in the World Health Organization (WHO) pharmacov...